Still, the results from ongoing and further randomized trials are needed to define optimal treatment and its timing for grade 2 astrocytoma patients, also when considering alternative treatment options, like targeting IDH mutation with inhibition or vaccination [4]. The gene discussed is IDH2; the disease is astrocytoma (excluding glioblastoma).